Clinical Trial Update: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

View source ↗

Summary

Amifampridine phosphate has received marketing approval for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndrome. This update relates to Catalys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Myasthenic Syndrome
• Lambert-eaton Myasthenic Syndrome

Drugs mentioned

• FIRDAPSE (AMIFAMPRIDINE PHOSPHATE)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome | Status: APPROVED_FOR_MARKETING